With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations

While the value of Cephalon's pipeline is "modest," the specialty pharma will provide Teva with an expanded portfolio of marketed branded drugs, commercial infrastructure and cost synergies, making integration execution critical.